The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. The antisense oligonucleotide comprises at least one modified nucleotide, wherein the antisense oligonucleotide suppresses expression of one or both of the chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT1) gene and the chondroitin sulfate N-acetylgalactosaminyltransferase-2 (CSGalNAcT2) gene.

The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. The antisense oligonucleotide comprises at least one modified nucleotide, wherein the antisense oligonucleotide suppresses expression of one or both of the chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT1) gene and the chondroitin sulfate N-acetylgalactosaminyltransferase-2 (CSGalNAcT2) gene.

This invention provides a highly functional antisense oligonucleotide that inhibits biosynthesis of chondroitin sulfate. The invention also provides an antisense oligonucleotide that suppresses expression of the chondroitin sulfate N-acetylgalactosaminyl-transferase-1 (CSGalNAc-T1) gene and has the properties (i) to (iv): (i) an antisense oligonucleotide is 13- to 25-mer in length; (ii) an antisense oligonucleotide comprises a gap region, a 3-wing region bound to the 3 end of the gap region, and a 5-wing region bound to the 5 end of the gap region; (iii) nucleotides in the 3-wing region and in the 5-wing region include at least one bridged nucleic acid and the bridged nucleic acid is scpBNA or AmNA; and (iv) an antisense oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2 to 31 or a sequence derived therefrom by substitution, deletion, or insertion of 1 or 2 nucleic acid bases.